DRW Securities’s Vertex Pharmaceuticals VRTX Stock Holding History

DRW Securities’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-746	Closed	-$335K	–	1755
2025 Q4	$335K	Buy	+746	New	+$322K	0.01%	621
2025 Q1	–	Sell	-1,189	Closed	-$479K	–	819
2024 Q4	$479K	Buy	+1,189	New	+$551K	0.02%	341
2024 Q3	–	Sell	-742	Closed	-$348K	–	759
2024 Q2	$348K	Sell	742 -1,225	-62%	-$532K	0.01%	381
2024 Q1	$822K	Buy	+1,967	New	+$832K	0.02%	193
2023 Q4	–	Sell	-611	Closed	-$212K	–	457
2023 Q3	$212K	Sell	611 -936	-61%	-$327K	﹤0.01%	303
2023 Q2	$544K	Buy	+1,547	New	+$521K	0.01%	197
2021 Q3	–	Sell	-1,085	Closed	-$219K	–	374
2021 Q2	$219K	Buy	+1,085	New	+$227K	0.01%	266
2020 Q2	–	Sell	-1,358	Closed	-$323K	–	338
2020 Q1	$323K	Buy	+1,358	New	+$312K	0.01%	203
2018 Q1	–	Sell	-3,552	Closed	-$532K	–	481
2017 Q4	$532K	Buy	+3,552	New	+$526K	0.06%	203
2015 Q3	–	Sell	-83,000	Closed	-$10.2M	–	110
2015 Q2	$10.2M	Buy	+83,000	New	+$10.5M	1.11%	6

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

DRW Securities's VRTX Position: Q1 2026 in Review

DRW Securities sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 746 shares — an estimated $335K sold.

DRW Securities first reported a position in VRTX in Q2 2015 and held it in 10 quarters. The position peaked at $10.2M in Q2 2015. 1,688 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

DRW Securities reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
DRW Securities sold 746 Vertex Pharmaceuticals shares in Q1 2026, an estimated $335K.
DRW Securities first reported a position in Vertex Pharmaceuticals in Q2 2015 and held it in 10 quarters.
DRW Securities's Vertex Pharmaceuticals position peaked at $10.2M in Q2 2015.
1,688 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on DRW Securities's 13F filing for Q1 2026, filed 13 May 2026.